Glück Conviction Score™ ⓘ
TVTX
Travere Therapeutics, Inc.
Effektiv: Neutral
Mittel
Bedeutung der Einstufung ⓘ
Insider
0,0
Keine Insider-Käufe
Institutionell
45,7
51 neu, 103 erhöht, -1106338K $ netto
Aktivist
57,3
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,69% (Stand: 31.05.2026)
Score-Verlauf (90 Tage)
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (12 Monate)
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 41.99 | +23.9 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 32.89 | +58.2 % vs SMA200 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 46.16 | EMA50: 42.24 | |
| MACD-Histogramm | Bullisch | 10 % | 0.274 | Bullisch | |
| RSI(14) | Neutral | 10 % | 68.6 | Neutral (30–70) | |
| Stoch %K(14) | Bärisch | 5 % | 93.4 | Überkauft | |
| ADX(14)+DI | Bullisch | 10 % | 40.3 | +DI: 31.9 / −DI: 10.6 | |
| Z-Score(60) | Bärisch | 5 % | 1.76 | Extrem überkauft | |
| 52W-Position | Bullisch | 5 % | 100.0 % | Hoch 52.04 / Tief 14.09 | |
| Bollinger(20,2σ) | Bärisch | 5 % | 113.9 % | Upper 50.68 / Mid 45.80 / Lower 40.91 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.3738 | R²=0.84 / annualisiert +237.5 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Coughlin Timothy | Director | Open Market Sale | -3.250 | 43,49 | -141.342,50 | -30,0% | |
| 2026-05-06 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -2.076 | 43,95 | -91.240,20 | -19,3% | |
| 2026-05-06 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -310 | 43,95 | -13.624,50 | -2,9% | |
| 2026-05-06 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -22.500 | 43,95 | -988.875,00 | -209,7% | |
| 2026-05-06 | ROTE WILLIAM E. | Officer, Chief Research Officer | Open Market Sale | -2.763 | 43,95 | -121.433,85 | -25,7% | |
| 2026-05-06 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -311 | 43,95 | -13.668,45 | -2,9% | |
| 2026-05-05 | Baynes Roy D. | Director | Open Market Sale | -4.500 | 46,65 | -209.925,00 | -44,5% | |
| 2026-05-05 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -2.174 | 46,65 | -101.417,10 | -21,5% | |
| 2026-05-05 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -2.181 | 46,65 | -101.743,65 | -21,6% | |
| 2026-05-05 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.174 | 46,65 | -101.417,10 | -21,5% | |
| 2026-05-05 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -2.174 | 46,65 | -101.417,10 | -21,5% | |
| 2026-05-04 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -20.000 | 45,00 | -900.000,00 | -190,8% | |
| 2026-05-04 | Meckler Jeffrey A | Director | Open Market Sale | -8.000 | 45,00 | -360.000,00 | -76,3% | |
| 2026-05-04 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -20.000 | 45,00 | -900.000,00 | -190,8% | |
| 2026-05-01 | Baynes Roy D. | Director | Open Market Sale | -9.750 | 44,22 | -431.145,00 | -91,4% | |
| 2026-04-22 | ROTE WILLIAM E. | Officer, Chief Research Officer | Open Market Sale | -9.100 | 39,09 | -355.719,00 | -75,4% | |
| 2026-04-15 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -56.815 | 41,01 | -2.329.983,15 | -494,1% | |
| 2026-04-15 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -20 | 42,66 | -853,20 | -0,2% | |
| 2026-04-15 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1.018 | 42,61 | -43.376,98 | -9,2% | |
| 2026-04-15 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.014 | 42,61 | -43.206,54 | -9,2% | |
| 2026-04-15 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -1.559 | 42,53 | -66.304,27 | -14,1% | |
| 2026-04-15 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -5.226 | 41,62 | -217.506,12 | -46,1% | |
| 2026-04-15 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -7.165 | 41,75 | -299.138,75 | -63,4% | |
| 2026-04-14 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -7.215 | 41,93 | -302.516,29 | -64,1% | |
| 2026-04-14 | Baynes Roy D. | Director | Open Market Sale | -26.000 | 41,07 | -1.067.820,00 | -226,4% | |
| 2026-04-14 | Baynes Roy D. | Director | Open Market Sale | -6.750 | 42,12 | -284.310,00 | -60,3% | |
| 2026-04-14 | LYONS GARY A | Director | Open Market Sale | -8.000 | 41,07 | -328.560,00 | -69,7% | |
| 2026-04-14 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -21.977 | 41,07 | -902.595,39 | -191,4% | |
| 2026-04-14 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -7.215 | 41,93 | -302.516,29 | -64,1% | |
| 2026-04-14 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -7.215 | 41,93 | -302.516,29 | -64,1% | |
| 2026-04-14 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -7.239 | 41,93 | -303.522,58 | -64,4% | |
| 2026-04-14 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -9 | 41,07 | -369,63 | -0,1% | |
| 2026-04-14 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -37.500 | 41,07 | -1.540.125,00 | -326,6% | |
| 2026-04-13 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -65 | 28,85 | -1.875,25 | -0,4% | |
| 2026-04-06 | Baynes Roy D. | Director | Open Market Sale | -10.000 | 33,00 | -330.000,00 | -70,0% | |
| 2026-04-01 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -34.902 | 30,55 | -1.066.256,10 | -226,1% | |
| 2026-04-01 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -10.000 | 30,00 | -300.000,00 | -63,6% | |
| 2026-04-01 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -25.098 | 31,46 | -789.583,08 | -167,4% | |
| 2026-03-16 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -10.000 | 28,09 | -280.861,00 | -59,6% | |
| 2026-02-20 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -60.000 | 30,10 | -1.805.766,00 | -382,9% | |
| 2026-02-17 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -4.321 | 28,26 | -122.120,10 | -25,9% | |
| 2026-02-17 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -5.679 | 27,50 | -156.195,22 | -33,1% | |
| 2026-02-04 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1.635 | 32,14 | -52.548,90 | -11,1% | |
| 2026-02-04 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -110 | 32,90 | -3.619,00 | -0,8% | |
| 2026-02-04 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -509 | 32,74 | -16.664,66 | -3,5% | |
| 2026-02-04 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -2.485 | 32,07 | -79.693,95 | -16,9% | |
| 2026-02-04 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -1.547 | 32,11 | -49.674,17 | -10,5% | |
| 2026-02-04 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -232 | 32,85 | -7.621,20 | -1,6% | |
| 2026-02-03 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -7.175 | 32,12 | -230.461,00 | -48,9% | |
| 2026-02-03 | ROTE WILLIAM E. | Officer, Chief Research Officer | Open Market Sale | -12.446 | 32,87 | -409.100,02 | -86,7% | |
| 2026-02-03 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -66.452 | 32,06 | -2.130.451,12 | -451,7% | |
| 2026-02-03 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -33.635 | 32,70 | -1.099.864,50 | -233,2% | |
| 2026-02-03 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -4.333 | 32,12 | -139.175,96 | -29,5% | |
| 2026-02-03 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -7.310 | 32,12 | -234.797,20 | -49,8% | |
| 2026-02-03 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -6.956 | 32,12 | -223.426,72 | -47,4% | |
| 2026-02-03 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -7.242 | 32,12 | -232.613,04 | -49,3% | |
| 2026-01-27 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -51.865 | 30,10 | -1.560.980,91 | -331,0% | |
| 2026-01-23 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -8.135 | 30,01 | -244.153,31 | -51,8% | |
| 2026-01-20 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -10.000 | 27,34 | -273.420,00 | -58,0% | |
| 2026-01-06 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -445 | 37,75 | -16.798,75 | -3,6% | |
| 2026-01-05 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -2.031 | 40,18 | -81.605,58 | -17,3% | |
| 2025-12-24 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -15.000 | 42,00 | -630.004,50 | -133,6% | |
| 2025-12-24 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -7.402 | 40,00 | -296.080,00 | -62,8% | |
| 2025-12-24 | ROTE WILLIAM E. | Officer, Chief Research Officer | Open Market Sale | -60.000 | 40,10 | -2.406.180,00 | -510,2% | |
| 2025-12-24 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -4.980 | 40,00 | -199.200,00 | -42,2% | |
| 2025-12-15 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -2.910 | 36,00 | -104.760,00 | -22,2% | |
| 2025-12-01 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -20.000 | 35,01 | -700.202,00 | -148,5% | |
| 2025-11-04 | Calvin Sandra | Officer, SVP, CHIEF ACCOUNTING OFFICER | Open Market Sale | -67.115 | 36,00 | -2.416.140,00 | -512,3% | |
| 2025-10-31 | Coughlin Timothy | Director | Open Market Sale | -18.000 | 35,03 | -630.601,20 | -133,7% | |
| 2025-10-31 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -5.591 | 35,00 | -195.685,00 | -41,5% | |
| 2025-10-29 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -27.128 | 30,12 | -817.073,66 | -173,3% | |
| 2025-10-28 | Heerma Peter | Officer, CHIEF COMMERCIAL OFFICER | Open Market Sale | -2.662 | 30,00 | -79.860,00 | -16,9% | |
| 2025-10-28 | Dube Eric M | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -92.872 | 30,38 | -2.821.358,49 | -598,2% | |
| 2025-09-22 | REED ELIZABETH E | Officer, Chief Legal Officer and GC | Open Market Sale | -10.000 | 25,00 | -250.000,00 | -53,0% | |
| 2025-09-04 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -119 | 19,71 | -2.345,49 | -0,5% | |
| 2025-09-03 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -454 | 18,20 | -8.262,80 | -1,8% | |
| 2025-08-27 | Cline Christopher R. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -470 | 17,31 | -8.135,70 | -1,7% | |
| 2025-07-01 | Inrig Jula | Officer, CHIEF MEDICAL OFFICER | Open Market Sale | -815 | 14,65 | -11.939,75 | -2,5% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 16.198.586 | 10.511.166 | 5.687.420 | 345.282.722 | Aufgestockt | +54,1% | |
| FMR LLC | 21.819.967 | 39.879.863 | -18.059.896 | 339.540.480 | Reduziert | -45,3% | |
| VANGUARD GROUP INC | 6.309.229 | 0 | 6.309.229 | 241.075.642 | Neu | +100,0% | |
| BlackRock, Inc. | 12.767.033 | 11.544.352 | 1.222.681 | 237.773.779 | Aufgestockt | +10,6% | |
| STATE STREET CORP | 4.959.988 | 4.756.666 | 203.322 | 147.361.243 | Aufgestockt | +4,3% | |
| ARMISTICE CAPITAL, LLC | 4.897.417 | 3.763.891 | 1.133.526 | 145.502.259 | Aufgestockt | +30,1% | |
| LINDEN ADVISORS LP | 101.062.000 | 85.562.000 | 15.500.000 | 127.919.176 | Aufgestockt | +18,1% | |
| PERCEPTIVE ADVISORS LLC | 4.142.551 | 4.278.180 | -135.629 | 123.075.190 | Reduziert | -3,2% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.045.812 | 0 | 4.045.812 | 120.201.075 | Neu | +100,0% | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 3.270.513 | 3.773.564 | -503.051 | 97.167.000 | Reduziert | -13,3% | |
| D. E. Shaw & Co., Inc. | 39.121.544 | 39.379.556 | -258.012 | 73.212.178 | Reduziert | -0,7% | |
| Kynam Capital Management, LP | 2.423.918 | 517.884 | 1.906.034 | 72.014.604 | Aufgestockt | +368,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.369.559 | 2.143.495 | 226.064 | 70.411.435 | Aufgestockt | +10,5% | |
| Context Capital Management, LLC | 52.933.000 | 57.457.000 | -4.524.000 | 66.936.425 | Reduziert | -7,9% | |
| RENAISSANCE TECHNOLOGIES LLC | 1.966.779 | 2.246.779 | -280.000 | 58.433.004 | Reduziert | -12,5% | |
| GOLDMAN SACHS GROUP INC | 6.402.721 | 7.803.212 | -1.400.491 | 56.997.236 | Reduziert | -17,9% | |
| Stephens Investment Management Group LLC | 1.798.466 | 1.721.623 | 76.843 | 53.432.425 | Aufgestockt | +4,5% | |
| Point72 Asset Management, L.P. | 5.203.783 | 0 | 5.203.783 | 51.692.036 | Neu | +100,0% | |
| TWO SIGMA INVESTMENTS, LP | 4.508.259 | 1.156.807 | 3.351.452 | 48.592.775 | Aufgestockt | +289,7% | |
| EMERALD ADVISERS, LLC | 1.557.196 | 1.594.184 | -36.988 | 46.264.293 | Reduziert | -2,3% | |
| Rock Springs Capital Management LP | 1.477.954 | 2.210.322 | -732.368 | 43.910.013 | Reduziert | -33,1% | |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 32.000.000 | 13.760.000 | 18.240.000 | 40.446.334 | Aufgestockt | +132,6% | |
| BANK OF AMERICA CORP /DE/ | 1.345.111 | 1.862.355 | -517.244 | 39.963.238 | Reduziert | -27,8% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1.282.518 | 901.404 | 381.114 | 38.103.610 | Aufgestockt | +42,3% | |
| MPM BioImpact LLC | 1.133.365 | 0 | 1.133.365 | 33.672.274 | Neu | +100,0% | |
| JPMORGAN CHASE & CO | 1.426.715 | 0 | 1.426.715 | 32.623.243 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.093.858 | 895.872 | 197.986 | 32.498.521 | Aufgestockt | +22,1% | |
| WELLINGTON MANAGEMENT GROUP LLP | 1.022.272 | 798.984 | 223.288 | 30.371.701 | Aufgestockt | +27,9% | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 977.000 | 2.927.000 | -1.950.000 | 29.026.670 | Reduziert | -66,6% | |
| EMERALD MUTUAL FUND ADVISERS TRUST | 945.033 | 948.459 | -3.426 | 28.076.930 | Reduziert | -0,4% | |
| Nuveen, LLC | 938.569 | 993.613 | -55.044 | 27.884.885 | Reduziert | -5,5% | |
| TWO SIGMA ADVISERS, LP | 725.500 | 0 | 725.500 | 27.721.355 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 925.919 | 881.680 | 44.239 | 27.509.054 | Aufgestockt | +5,0% | |
| UBS Group AG | 2.083.757 | 422.619 | 1.661.138 | 27.001.252 | Aufgestockt | +393,1% | |
| Fiera Capital Corp | 900.868 | 874.053 | 26.815 | 26.764.789 | Aufgestockt | +3,1% | |
| TANG CAPITAL MANAGEMENT LLC | 700.000 | 0 | 700.000 | 26.747.000 | Neu | +100,0% | |
| BARCLAYS PLC | 1.109.461 | 736.530 | 372.931 | 25.848.534 | Aufgestockt | +50,6% | |
| Caption Management, LLC | 864.500 | 691.400 | 173.100 | 25.684.295 | Aufgestockt | +25,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 790.812 | 808.189 | -17.377 | 23.495.025 | Reduziert | -2,2% | |
| NORTHERN TRUST CORP | 781.418 | 761.473 | 19.945 | 23.215.929 | Aufgestockt | +2,6% | |
| RA CAPITAL MANAGEMENT, L.P. | 746.841 | 0 | 746.841 | 22.188.646 | Neu | +100,0% | |
| ADVENT CAPITAL MANAGEMENT /DE/ | 17.392.000 | 14.212.000 | 3.180.000 | 22.025.649 | Aufgestockt | +22,4% | |
| Ensign Peak Advisors, Inc | 715.707 | 805.215 | -89.508 | 21.263.655 | Reduziert | -11,1% | |
| Qube Research & Technologies Ltd | 669.159 | 406.221 | 262.938 | 19.880.714 | Aufgestockt | +64,7% | |
| PANAGORA ASSET MANAGEMENT INC | 592.912 | 587.354 | 5.558 | 17.615.416 | Aufgestockt | +0,9% | |
| Aberdeen Group plc | 557.147 | 518.357 | 38.790 | 16.552.837 | Aufgestockt | +7,5% | |
| JANE STREET GROUP, LLC | 842.380 | 690.173 | 152.207 | 16.494.207 | Aufgestockt | +22,1% | |
| Soleus Capital Management, L.P. | 546.000 | 0 | 546.000 | 16.221.660 | Neu | +100,0% | |
| Eversept Partners, LP | 542.610 | 1.174.968 | -632.358 | 16.120.943 | Reduziert | -53,8% | |
| Invesco Ltd. | 523.711 | 474.075 | 49.636 | 15.559.454 | Aufgestockt | +10,5% |
Top-Fondshalter (Stand: 31.03.2026) ⓘ
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 16.198.586 | 10.511.166 | +54,1% | 345.282.722 | 10,19 |
| FMR LLC | 21.819.967 | 39.879.863 | -45,3% | 339.540.480 | 10,02 |
| BlackRock, Inc. | 12.767.033 | 11.544.352 | +10,6% | 237.773.779 | 7,01 |
| STATE STREET CORP | 4.959.988 | 4.756.666 | +4,3% | 147.361.243 | 4,35 |
| ARMISTICE CAPITAL, LLC | 4.897.417 | 3.763.891 | +30,1% | 145.502.259 | 4,29 |
| LINDEN ADVISORS LP | 101.062.000 | 85.562.000 | +18,1% | 127.919.176 | 3,77 |
| PERCEPTIVE ADVISORS LLC | 4.142.551 | 4.278.180 | -3,2% | 123.075.190 | 3,63 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.045.812 | 0 | +100,0% | 120.201.075 | 3,55 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 3.270.513 | 3.773.564 | -13,3% | 97.167.000 | 2,87 |
| D. E. Shaw & Co., Inc. | 39.121.544 | 39.379.556 | -0,7% | 73.212.178 | 2,16 |
| Kynam Capital Management, LP | 2.423.918 | 517.884 | +368,0% | 72.014.604 | 2,12 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.369.559 | 2.143.495 | +10,5% | 70.411.435 | 2,08 |
| Context Capital Management, LLC | 52.933.000 | 57.457.000 | -7,9% | 66.936.425 | 1,97 |
| RENAISSANCE TECHNOLOGIES LLC | 1.966.779 | 2.246.779 | -12,5% | 58.433.004 | 1,72 |
| GOLDMAN SACHS GROUP INC | 6.402.721 | 7.803.212 | -17,9% | 56.997.236 | 1,68 |
| Stephens Investment Management Group LLC | 1.798.466 | 1.721.623 | +4,5% | 53.432.425 | 1,58 |
| TWO SIGMA INVESTMENTS, LP | 4.508.259 | 1.156.807 | +289,7% | 48.592.775 | 1,43 |
| EMERALD ADVISERS, LLC | 1.557.196 | 1.594.184 | -2,3% | 46.264.293 | 1,36 |
| Rock Springs Capital Management LP | 1.477.954 | 2.210.322 | -33,1% | 43.910.013 | 1,30 |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 32.000.000 | 13.760.000 | +132,6% | 40.446.334 | 1,19 |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 31.03.2026 | ✓ | 278 | 431,1 | 4.064 |
| 31.12.2025 | ✓ | 299 | 435,2 | 4.651 |
| 30.09.2025 | ✓ | 259 | 361,1 | 2.902 |
| 30.06.2025 | ✓ | 232 | 406,7 | 1.829 |
| 31.03.2025 | ✓ | 239 | 460,4 | 2.297 |
| 31.12.2024 | ✓ | 212 | 441,3 | 2.111 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) ⓘ |
|---|---|---|
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 3.773.564 | 144.188.000 |
| Fiera Capital Corp | 874.053 | 33.397.565 |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 13.760.000 | 19.679.515 |
| LOOMIS SAYLES & CO L P | 238.924 | 9.129.286 |
| M&G Plc | 5.131.000 | 7.286.020 |
| Palisades Investment Partners, LLC | 137.768 | 5.264.115 |
| Elmind Capital, LP | 110.000 | 4.203.100 |
| Informed Momentum Co LLC | 109.404 | 4.180.327 |
| Voleon Capital Management LP | 102.553 | 3.918.550 |
| KVP Capital Advisors, LP | 91.000 | 3.477.110 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| Context Capital Management, LLC | 57.457.000 | 57.410.646 | +123852.6 % | 81.991.139 |
| FMR LLC | 39.879.863 | 33.228.715 | +499.6 % | 410.531.102 |
| GOLDMAN SACHS GROUP INC | 7.803.212 | 4.907.309 | +169.5 % | 79.823.950 |
| MILLENNIUM MANAGEMENT LLC | 15.996.065 | 2.761.696 | +20.9 % | 31.873.913 |
| TORONTO DOMINION BANK | 3.325.003 | 2.514.000 | +310.0 % | 4.713.303 |
| STATE STREET CORP | 4.756.666 | 1.538.827 | +47.8 % | 181.752.208 |
| LORD, ABBETT & CO. LLC | 13.587.822 | 1.268.903 | +10.3 % | 24.346 |
| CAPSTONE INVESTMENT ADVISORS, LLC | 1.000.000 | 986.560 | +7340.5 % | 1.427.000 |
| Hudson Bay Capital Management LP | 900.300 | 584.000 | +184.6 % | 34.400.463 |
| RENAISSANCE TECHNOLOGIES LLC | 2.246.779 | 494.665 | +28.2 % | 85.849.426 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile ⓘ | Δ % ⓘ | Wert (USD) ⓘ |
|---|---|---|---|---|
| AGF MANAGEMENT LTD | 1.050.000 | -7.750.000 | -88.1 % | 1.493.100 |
| JANUS HENDERSON GROUP PLC | 10.511.166 | -6.444.494 | -38.0 % | 401.715.922 |
| ADVENT CAPITAL MANAGEMENT /DE/ | 14.212.000 | -5.970.000 | -29.6 % | 20.388.016 |
| Polar Capital Holdings Plc | 2.500.000 | -5.500.000 | -68.8 % | 3.543.750 |
| LINDEN ADVISORS LP | 85.562.000 | -4.944.000 | -5.5 % | 122.037.403 |
| Point72 Asset Management, L.P. | 5.203.783 | -4.796.217 | -48.0 % | 51.692.036 |
| D. E. Shaw & Co., Inc. | 39.379.556 | -4.568.696 | -10.4 % | 96.399.958 |
| ARMISTICE CAPITAL, LLC | 3.763.891 | -2.960.109 | -44.0 % | 143.818.275 |
| NEW YORK STATE COMMON RETIREMENT FUND | 1.049.557 | -955.257 | -47.6 % | 10.673.173 |
| JENNISON ASSOCIATES LLC | 256.335 | -828.015 | -76.4 % | 9.794.559 |
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Zweck |
|---|---|---|---|---|---|---|
| 15.05.2026 | Steven Boyd | Passiv (13G) | 5,27 % | 4.897.417 | +1,06 pp | |
| 15.05.2026 | Armistice Capital, LLC | Passiv (13G) | 5,27 % | 4.897.417 | +1,06 pp | |
| 30.04.2026 | Vanguard Capital Management | Passiv (13G) | 5,09 % | 4.699.424 | Neu | |
| 27.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -6,74 pp | |
| 17.02.2026 | Joseph Edelman | Passiv (13G/A) | 4,80 % | 4.278.180 | -0,70 pp | |
| 17.02.2026 | Perceptive Life Sciences Master Fund, Ltd. | Passiv (13G/A) | 4,80 % | 4.278.180 | -0,70 pp | |
| 17.02.2026 | Perceptive Advisors LLC | Passiv (13G/A) | 4,80 % | 4.278.180 | -0,70 pp | |
| 17.02.2026 | Armistice Capital, LLC | Passiv (13G/A) | 4,21 % | 3.763.891 | -3,31 pp | |
| 17.02.2026 | Steven Boyd | Passiv (13G/A) | 4,21 % | 3.763.891 | -3,31 pp | |
| 13.02.2026 | Macquarie Management Holdings Inc | Passiv (13G/A) | Ausstieg | 0 | -5,41 pp | |
| 13.02.2026 | Macquarie Group Limited | Passiv (13G/A) | Ausstieg | 0 | -5,41 pp | |
| 13.02.2026 | Macquarie Investment Management Business Trust | Passiv (13G/A) | Ausstieg | 0 | -5,41 pp | |
| 09.02.2026 | STATE STREET CORPORATION | Passiv (13G) | 5,30 % | 4.756.666 | +1,70 pp | |
| 08.01.2026 | FMR LLC | Passiv (13G) | 11,70 % | 10.567.303 | Neu | |
| 08.01.2026 | Abigail P. Johnson | Passiv (13G) | 11,70 % | 10.567.303 | Neu | |
| 14.11.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 11,90 % | 10.599.660 | -0,90 pp | |
| 14.11.2025 | Steven Boyd | Passiv (13G/A) | 7,52 % | 6.724.000 | -2,44 pp | |
| 14.11.2025 | Armistice Capital, LLC | Passiv (13G/A) | 7,52 % | 6.724.000 | -2,44 pp | |
| 14.10.2025 | Perceptive Advisors LLC | Passiv (13G) | 5,50 % | 4.895.615 | +2,50 pp | |
| 14.10.2025 | Joseph Edelman | Passiv (13G) | 5,50 % | 4.895.615 | +2,50 pp | |
| 14.10.2025 | Perceptive Life Sciences Master Fund, Ltd. | Passiv (13G) | 5,50 % | 4.895.615 | +2,50 pp | |
| 15.08.2025 | Armistice Capital, LLC | Passiv (13G/A) | 9,96 % | 8.876.000 | -0,03 pp | |
| 15.08.2025 | Steven Boyd | Passiv (13G/A) | 9,96 % | 8.876.000 | -0,03 pp | |
| 07.08.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G/A) | 12,80 % | 11.339.864 | +4,30 pp | |
| 29.07.2025 | The Vanguard Group | Passiv (13G/A) | 6,74 % | 5.994.283 | +1,09 pp | |
| 15.05.2025 | Armistice Capital, LLC | Passiv (13G/A) | 9,99 % | 8.872.000 | +0,37 pp | |
| 15.05.2025 | Steven Boyd | Passiv (13G/A) | 9,99 % | 8.872.000 | +0,37 pp | |
| 15.05.2025 | Rock Springs Capital Master Fund LP | Passiv (13G/A) | 2,60 % | 2.327.521 | -2,21 pp | |
| 15.05.2025 | Rock Springs Capital LLC | Passiv (13G/A) | 3,30 % | 2.921.196 | -2,42 pp | |
| 15.05.2025 | Rock Springs Capital Management LP | Passiv (13G/A) | 3,30 % | 2.921.196 | -2,42 pp | |
| 15.05.2025 | Mark Bussard | Passiv (13G/A) | 3,30 % | 2.921.196 | -2,42 pp | |
| 15.05.2025 | Kris Jenner | Passiv (13G/A) | 3,30 % | 2.921.196 | -2,42 pp | |
| 15.05.2025 | Macquarie Management Holdings Inc | Passiv (13G/A) | 5,41 % | 4.797.314 | +0,51 pp | |
| 15.05.2025 | Macquarie Group Limited | Passiv (13G/A) | 5,41 % | 4.797.314 | +0,51 pp | |
| 15.05.2025 | Macquarie Investment Management Business Trust | Passiv (13G/A) | 5,41 % | 4.797.314 | +0,51 pp | |
| 14.05.2025 | JANUS HENDERSON GROUP PLC | Passiv (13G) | 8,50 % | 7.566.963 | Neu | |
| 30.04.2025 | The Vanguard Group | Passiv (13G/A) | 5,65 % | 5.014.020 | -2,10 pp | |
| 17.04.2025 | BlackRock, Inc. | Passiv (13G/A) | 7,50 % | 6.689.435 | -1,90 pp | |
| 14.02.2025 | Steven Boyd | Passiv (13G/A) | 9,62 % | 7.358.000 | -0,38 pp | |
| 14.02.2025 | Armistice Capital, LLC | Passiv (13G/A) | 9,62 % | 7.358.000 | -0,38 pp |
Stammdaten
Travere Therapeutics, Inc., ein Biopharmaka-Unternehmen, konzentriert sich auf Identifikation, Entwicklung, Kommerzialisierung und Bereitstellung von Therapien zur Behandlung seltener Erkrankungen. Die vermarkteten Produkte des Unternehmens umfassen Chenodal, eine synthetische orale Darreichungsform von Chenodesoxycholsäure zur Behandlung von radiodichten Steinen in Gallenblasen; Cholbam, eine Cholsäure-Kapsel zur Behandlung von pädiatrischen und erwachsenen Patienten mit Störungen der Gallensäuresynthese aufgrund von Einzelenzymdefekten sowie zur adjuvanten Behandlung von Patienten mit peroxisomalen Störungen; sowie Thiola und Thiola EC, eine Tiopronin-Tablette zur Behandlung von homozygöser Cystinurie. Die Produktkandidaten des Unternehmens umfassen ferner Sparsentan, das sich in Phase-III-Studien zur Behandlung von fokal segmentaler Glomerulosklerose und IgA-Nephropathie befindet; sowie TVT-058, ein neuartiger humaner Enzymersatz-Kandidat in Phase-I/II-Studien zur Behandlung der klassischen Homocystinurie. Das Unternehmen hat eine Kooperations- und Entwicklungsvereinbarung mit dem National Center for Advancing Translational Sciences der National Institutes of Health sowie mit Patientenvertretungsorganisationen CDG Care und Alagille Syndrome Alliance zur Identifikation potenzieller Small-Molecule-Therapeutika für NGLY1-Mangel und Alagille-Syndrom. Das Unternehmen war ursprünglich unter dem Namen Retrophin, Inc. bekannt und änderte seinen Namen im November 2020 zu Travere Therapeutics, Inc. Travere Therapeutics, Inc. wurde 2008 gegründet und hat seinen Sitz in San Diego, Kalifornien.
Unternehmen & Branche
| Name | Travere Therapeutics, Inc. |
|---|---|
| Ticker | TVTX |
| CIK | 0001438533 |
| Boerse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 89422G107 |
|---|---|
| ISIN | US89422G1076 |
| Typ | Common Stock |
| Marktkapitalisierung | 4,39 Mrd. USD |
| Beta | 1,10 |
Bewertung
| KBV (P/B) | 38,23 vs. 6,42 (2021) ▲ |
|---|---|
| KUV (P/S) | 8,94 vs. 14,71 (2021) ▼ |
| FCF-Rendite | 0,9 % vs. -1,0 % (2021) ▲ |
Qualität & Bilanz
| Bruttomarge | 97,9 % vs. 97,1 % (2021) ≈ |
|---|---|
| Operative Marge | -12,8 % vs. -151,3 % (2021) ▲ |
| Nettomarge | -5,2 % vs. -136,6 % (2021) ▲ |
| ROIC | -19,4 % vs. -53,4 % (2021) ▲ |
| Zinsdeckungsgrad | -5,8 vs. -10,1 (2021) ▲ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | Verlauf |
|---|---|---|---|---|---|---|
| Bewertung | ||||||
| KBV (P/B) | 6,42 | 31,55 | 3,37 | 25,79 | 30,26 | |
| KUV (P/S) | 14,71 | 12,35 | 4,67 | 6,53 | 7,08 | |
| FCF-Rendite | -1,0 % | -13,8 % | -41,4 % | -15,6 % | 1,1 % | |
| Qualität & Bilanz | ||||||
| Bruttomarge | 97,1 % | 96,0 % | 92,1 % | 96,7 % | 97,9 % | |
| Operative Marge | -151,3 % | -292,2 % | -267,2 % | -138,9 % | -12,8 % | |
| Nettomarge | -136,6 % | -254,4 % | -76,7 % | -137,9 % | -5,2 % | |
| ROIC | -53,4 % | -372,3 % | -48,8 % | -393,7 % | -19,4 % | |
| Zinsdeckungsgrad | -10,1 | -29,1 | -34,3 | -29,0 | -5,8 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Finanzkennzahlen (SEC XBRL) ⓘ
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 127.199.000 | -37.102.000 | -0,40 | 555.188.000 | 98.728.000 |
| 2025-12-31 | 10-K | 490.728.000 | -25.546.000 | -0,29 | 605.191.000 | 114.828.000 |
| 2025-09-30 | 10-Q | 164.859.000 | 25.706.000 | 0,28 | 538.581.000 | 73.564.000 |
| 2025-06-30 | 10-Q | 114.449.000 | -12.755.000 | -0,14 | 555.309.000 | 32.747.000 |
| 2025-05-31 | 10-Q | 17.500.000 | ||||
| 2025-05-31 | 10-K | 17.500.000 | ||||
| 2025-03-31 | 10-Q | 81.732.000 | -41.226.000 | -0,47 | 548.799.000 | 32.823.000 |
| 2024-12-31 | 10-K | 233.175.000 | -321.545.000 | -4,08 | 594.125.000 | 59.077.000 |
| 2024-09-30 | 10-Q | 62.898.000 | -54.811.000 | -0,70 | 504.410.000 | -30.454.000 |
| 2024-06-30 | 10-Q | 54.116.000 | -70.409.000 | -0,91 | 551.121.000 | 15.147.000 |
| 2024-03-31 | 10-Q | 41.374.000 | -136.061.000 | -1,76 | 663.547.000 | 74.071.000 |
| 2024-01-31 | 10-Q | 8.300.000 | ||||
| 2024-01-31 | 10-K | 8.300.000 | ||||
| 2023-12-31 | 10-K | 145.238.000 | -111.399.000 | -1,50 | 788.913.000 | 200.810.000 |
| 2023-09-30 | 10-Q | 37.095.000 | 150.735.000 | 1,97 | 832.850.000 | 279.766.000 |
| 2023-06-30 | 10-Q | 32.196.000 | -85.630.000 | -1,13 | 736.429.000 | 116.485.000 |
| 2023-03-31 | 10-Q | 30.888.000 | -86.331.000 | -1,27 | 808.231.000 | 189.140.000 |
| 2022-12-31 | 10-K | 109.460.000 | -278.482.000 | -4,37 | 672.585.000 | 42.851.000 |
| 2022-09-30 | 10-Q | 28.075.000 | -69.656.000 | -1,09 | 726.215.000 | 100.676.000 |
| 2022-06-30 | 10-Q | 54.167.000 | -67.032.000 | -1,05 | 779.494.000 | 156.713.000 |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Product | 410,5 Mio. | 226,7 Mio. | 127,5 Mio. | 98,0 Mio. | 210,8 Mio. | 45,5 % | +81,1% | |
| FILSPARI | 322,0 Mio. | 132,2 Mio. | 29,2 Mio. | – | – | 35,7 % | +143,5% | |
| Tiopronin Products | 88,5 Mio. | 94,5 Mio. | 98,3 Mio. | 98,0 Mio. | 115,1 Mio. | 9,8 % | -6,4% | |
| License | 80,3 Mio. | 6,5 Mio. | 17,7 Mio. | 11,5 Mio. | 16,7 Mio. | 8,9 % | +1141,0% | |
| Bile Acid Products | – | – | – | – | 95,7 Mio. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 04.05.2026 | 127,2 Mio. USD | -0,40 |
| Q3 2025 | 30.09.2025 | 30.10.2025 | 164,9 Mio. USD | 0,28 |
| Q2 2025 | 30.06.2025 | 06.08.2025 | 114,4 Mio. USD | -0,14 |
| Q1 2025 | 31.03.2025 | 04.05.2026 | 81,7 Mio. USD | -0,47 |
| Q3 2024 | 30.09.2024 | 30.10.2025 | 62,9 Mio. USD | -0,70 |
| Q2 2024 | 30.06.2024 | 06.08.2025 | 54,1 Mio. USD | -0,91 |
| Q1 2024 | 31.03.2024 | 01.05.2025 | 41,4 Mio. USD | -1,76 |
| Q3 2023 | 30.09.2023 | 31.10.2024 | 37,1 Mio. USD | 1,97 |
| Q2 2023 | 30.06.2023 | 01.08.2024 | 32,2 Mio. USD | -1,13 |
Einreichungs-Historie (10-K / 10-Q)
SEC-Einreichungs-Historie der Quartalsberichte (10-Q) und Jahresberichte
(10-K) der letzten sechs Jahre. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 04.05.2026 | 10-Q | – | – | SEC » |
| 19.02.2026 | 10-K | 31.12.2025 | 50 Tage | SEC » |
| 30.10.2025 | 10-Q | 30.09.2025 | 30 Tage | SEC » |
| 06.08.2025 | 10-Q | 30.06.2025 | 37 Tage | SEC » |
| 01.05.2025 | 10-Q | 31.03.2025 | 31 Tage | SEC » |
| 21.02.2025 | 10-K | 31.12.2024 | 52 Tage | SEC » |
| 31.10.2024 | 10-Q | 30.09.2024 | 31 Tage | SEC » |
| 01.08.2024 | 10-Q | 30.06.2024 | 32 Tage | SEC » |
| 06.05.2024 | 10-Q | 31.03.2024 | 36 Tage | SEC » |
| 20.02.2024 | 10-K | 31.12.2023 | 51 Tage | SEC » |
| 07.11.2023 | 10-Q | 30.09.2023 | 38 Tage | SEC » |
| 03.08.2023 | 10-Q | 30.06.2023 | 34 Tage | SEC » |
| 04.05.2023 | 10-Q | 31.03.2023 | 34 Tage | SEC » |
| 23.02.2023 | 10-K | 31.12.2022 | 54 Tage | SEC » |
| 27.10.2022 | 10-Q | 30.09.2022 | 27 Tage | SEC » |
| 04.08.2022 | 10-Q | 30.06.2022 | 35 Tage | SEC » |
| 05.05.2022 | 10-Q | 31.03.2022 | 35 Tage | SEC » |
| 24.02.2022 | 10-K | 31.12.2021 | 55 Tage | SEC » |
| 29.10.2021 | 10-Q | 30.09.2021 | 29 Tage | SEC » |
| 29.07.2021 | 10-Q | 30.06.2021 | 29 Tage | SEC » |
| 06.05.2021 | 10-Q | 31.03.2021 | 36 Tage | SEC » |
| 01.03.2021 | 10-K | 31.12.2020 | 60 Tage | SEC » |
| 05.11.2020 | 10-Q | 30.09.2020 | 36 Tage | SEC » |
| 31.07.2020 | 10-Q | 30.06.2020 | 31 Tage | SEC » |
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 17.08.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 of Form 8-K, this Current Report on Form 8-K/A is being filed as an amendment to the Initial Form 8-K to… |
| 12.05.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 20.04.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 06.01.2022 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 12.10.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 17.09.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 14.09.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 19.05.2021 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 19.05.2020 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-04-28 | 621 | 40,81 | 25.343 |
| 2026-04-27 | 1.305 | 40,50 | 52.853 |
| 2026-04-23 | 517 | 40,09 | 20.727 |
| 2026-04-22 | 4.184 | 38,78 | 162.256 |
| 2026-04-21 | 2.930 | 40,29 | 118.050 |
| 2026-04-20 | 7.615 | 40,77 | 310.464 |
| 2026-04-15 | 59.592 | 42,13 | 2.510.611 |
| 2026-04-14 | 2.439 | 30,70 | 74.877 |
| 2026-04-06 | 74.414 | 30,44 | 2.265.162 |
| 2026-04-02 | 513 | 31,42 | 16.118 |
| 2026-03-24 | 14 | 27,75 | 389 |
| 2026-03-23 | 57 | 26,84 | 1.530 |
| 2026-03-02 | 2.255 | 29,79 | 67.176 |
| 2026-02-25 | 427 | 30,88 | 13.186 |
| 2026-02-06 | 1.229 | 29,47 | 36.219 |
| 2026-01-20 | 5.161 | 27,87 | 143.837 |
| 2026-01-16 | 537 | 28,40 | 15.251 |
| 2026-01-14 | 29.253 | 29,11 | 851.555 |
| 2026-01-08 | 65.769 | 36,28 | 2.386.099 |
| 2025-12-30 | 813 | 38,88 | 31.609 |
| 2025-12-23 | 1.484 | 36,50 | 54.166 |
| 2025-12-19 | 2.756 | 34,49 | 95.054 |